Lineage Cell Therapeutics Q1 2024: rev $1.4M, net loss $6.5M; new Genentech OpRegen deal

Lineage Cell Therapeutics, Inc.

2024-Q1 EPS reported -$0.04 revenue$1,444,000

Revenue of $1.4M, down from $2.4M YoY; net loss attributable $6.5M ($0.04/sh) vs $4.4M ($0.03/sh).
Cash $43.6M; expected to fund operations into Q3 2025.
New services agreement with Genentech to support OpRegen clinical and manufacturing activities.
OpRegen Phase 1/2a long-term data: mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients.
OPC1 clinical study start-up underway; received CIRM grant for 2nd Annual SCI Investor Symposium.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lineage Cell Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $1.4 million.

Period: the quarter ended March 31, 2024
Revenue: $1.4 million
Result: reported results

Exact text from the filing

Total revenues for the three months ended March 31, 2024 were approximately $1.4 million

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.